Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-26T05:24:24.695Z Has data issue: false hasContentIssue false
  • English
  • Français

Amantadine Treatment for Refractory Pain and Fatigue in Patients with Multiple Sclerosis

Published online by Cambridge University Press:  18 September 2015

Susumu Chiba ,
Michiko Ito  and
Hiroyuki Matsumoto
Susumu Chiba
Affiliation:
Department of Rehabilitation and Neurology, Sapporo Medical College, Sapporo
Michiko Ito
Affiliation:
Department of Rehabilitation and Neurology, Sapporo Medical College, Sapporo
Hiroyuki Matsumoto
Affiliation:
Department of Rehabilitation and Neurology, Sapporo Medical College, Sapporo
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Correspondence
Information
Canadian Journal of Neurological Sciences , Volume 19 , Issue 2 , May 1992 , pp. 309
Copyright
Copyright © Canadian Neurological Sciences Federation 1992

References

1.The Canadian MS Research Group. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987; 14:273–278.CrossRefGoogle Scholar
2.Cohen, RA, Fisher, M.Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989; 46: 676–680.CrossRefGoogle ScholarPubMed
3.Rosenberg, GA, Appenzeller, O.Amantadine, fatigue, and multiple sclerosis. Arch Neurol 1988; 45: 1104–1106.Google ScholarPubMed